Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Feb;29(2):271–277. doi: 10.1128/aac.29.2.271

Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administration.

D B Lakings, E Novak, J M Friis, C M Lunan, L M Paxton
PMCID: PMC176389  PMID: 3717932

Abstract

The pharmacokinetics of cefpimizole (free acid equivalents of cefpimizole sodium), a broad-spectrum cephalosporin antibiotic, were evaluated after intramuscular administration of single doses (dose range, 100 to 1,000 mg) and multiple doses (dose range, 500 to 2,000 mg) given b.i.d. for 6 or 11 days. The kinetics after intramuscular administration correspond to a one-compartment model with first-order input. The apparent volume of distribution of the absorbed dose averaged 18.6 +/- 3.4 (standard deviation) liters for 58 individuals; the absorption-phase and elimination-phase rate constants averaged 2.53 +/- 1.16 h-1 (half-life, 0.27 h) and 0.338 +/- 0.041 h-1 (half-life, 2.05 h), respectively; and the mean residence time was 3.43 +/- 0.43 h. The total body clearance of the absorbed dose after single-dose intramuscular administration was 102 +/- 13 ml/min. The primary route of elimination was renal with 73 to 83% of the administered dose excreted in the urine as unchanged drug. Renal clearance averaged 81 +/- 13 ml/min. Dose proportionality was obtained from area under the plasma curve, concentration maximum in plasma, and cumulative urinary excretion levels. Multiple-dose evaluation of intramuscular administration of cefpimizole indicated no apparent change in the absorption or elimination phases after b.i.d. dosing for 6 or 11 days. The kinetic parameters determined from multiple-dose plasma and urine levels were in close agreement with the same parameters calculated from single-dose results. No apparent accumulation of cefpimizole occurred, and nondetectable levels of drug were observed in the 24-h plasma and 24- to 48-h urine specimen after administration of the last dose. The kinetics of cefpimizole after intramuscular administration were similar to the kinetics obtained after intravenous infusion.

Full text

PDF
271

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acar J. F., Guibert J., Kitzis M. D. Cinétique du céfotaxime chez le sujet normal. Nouv Presse Med. 1981 Feb 26;10(8):559–563. [PubMed] [Google Scholar]
  2. Ings R. M., Fillastre J. P., Godin M., Leroy A., Humbert G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Rev Infect Dis. 1982 Sep-Oct;4 (Suppl):S379–S391. doi: 10.1093/clinids/4.supplement_2.s379. [DOI] [PubMed] [Google Scholar]
  3. Israel K. S., Black H. R., Brier G. L., Wolny J. D., DeSante K. A. Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects. Antimicrob Agents Chemother. 1982 Jul;22(1):94–102. doi: 10.1128/aac.22.1.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Lakings D. B., Friis J. M., Brown R. J., Allen H. R. Pharmacokinetics of cefpimizole in normal humans after single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother. 1984 Dec;26(6):802–806. doi: 10.1128/aac.26.6.802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Lakings D. B., Wozniak J. M. High-performance liquid chromatographic methods for the determination of cefpimizole in plasma and urine. J Chromatogr. 1984 Jun 8;308:261–271. doi: 10.1016/s0021-9673(01)87552-x. [DOI] [PubMed] [Google Scholar]
  6. Meyers B. R., Srulevitch E. S., Jacobson J., Hirschman S. Z. Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers. Antimicrob Agents Chemother. 1983 Nov;24(5):812–814. doi: 10.1128/aac.24.5.812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Neu H. C., Labthavikul P. In vitro activity and beta-lactamase stability of U-63196E, a novel cephalosporin. Antimicrob Agents Chemother. 1983 Sep;24(3):375–382. doi: 10.1128/aac.24.3.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Neu H. C., Srinivasan S. Pharmacology of ceftizoxime compared with that of cefamandole. Antimicrob Agents Chemother. 1981 Sep;20(3):366–369. doi: 10.1128/aac.20.3.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ohnishi H., Inaba H., Mochizuki H., Kosuzume H. Mechanism of action of AC-1370 on phagocyte functions. Antimicrob Agents Chemother. 1984 Jan;25(1):88–92. doi: 10.1128/aac.25.1.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ohnishi H., Kosuzume H., Inaba H., Okura M., Mochizuki H., Suzuki Y., Fujii R. Effects of AC-1370, a new semisynthetic cephalosporin, on phagocyte functions. Antimicrob Agents Chemother. 1983 Jun;23(6):874–880. doi: 10.1128/aac.23.6.874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Srinivasan S., Francke E. L., Neu H. C. Comparative pharmacokinetics of cefoperazone and cefamandole. Antimicrob Agents Chemother. 1981 Feb;19(2):298–301. doi: 10.1128/aac.19.2.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Srinivasan S., Fu K. P., Neu H. C. Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. Antimicrob Agents Chemother. 1981 Feb;19(2):302–305. doi: 10.1128/aac.19.2.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Standiford H. C., Drusano G. L., McNamee W. B., Tatem B., Ryan P. A., Schimpff S. C. Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers. Rev Infect Dis. 1982 Nov-Dec;4 (Suppl):S585–S594. doi: 10.1093/clinids/4.supplement_3.s585. [DOI] [PubMed] [Google Scholar]
  14. Yasuda N., Iwagami H., Nakanishi E., Nakamiya T., Sasaki Y., Murata T. Synthesis and antibacterial activity of 6- and 7-[2-(5-carboxyimidazole-4-carboxamido)phenylacetamido]-penicillins and cephalosporins. J Antibiot (Tokyo) 1983 Mar;36(3):242–249. doi: 10.7164/antibiotics.36.242. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES